Rodin Therapeutics Appoints Adam J. Rosenberg as Chief Executive Officer
CAMBRIDGE, MA – October 6, 2015 – Rodin Therapeutics, a biotechnology company applying insights from epigenetics to develop novel therapeutics for neurological disorders, today announced that its Board of Directors has appointed Adam J. Rosenberg as Chief Executive Officer. Mr. Rosenberg brings almost 20 years of entrepreneurial and transactional leadership, and will also be appointed to Rodin’s Board of Directors.
“We are very excited to have Adam join Rodin as we continue to make important progress with our HDAC2 inhibitor program for cognition, including Alzheimer’s Disease,” said Bruce Booth, Partner at Atlas Venture and Chairman of Rodin’s Board of Directors, who also co-founded and served as Rodin’s acting CEO until Mr. Rosenberg’s hiring. “Adam’s strong track record of leadership and operational expertise with emerging companies, particularly in neuroscience, as well as his strong corporate development and transactional background, will serve Rodin well as we embark on our next stage of growth.”
Since its inception within Atlas Venture’s company-creating seed program in March 2013, Rodin has advanced its internal pipeline of epigenetic modulators and obtained an exclusive license to an additional chemical series discovered at the Broad Institute. Important collaborations with co-founding structure-accelerated lead discovery partner Proteros Biostructures, as well as with the Alzheimer’s Drug Discovery Foundation, have been successfully put in place as well.
“I am excited to be joining Rodin and its strong team to rapidly advance its proprietary epigenetics platform to diseases with significant unmet need, such as Alzheimer’s Disease,” said Mr. Rosenberg. “With compelling internal and external preclinical data supporting our approach of targeting HDAC2 inhibition to improve learning and memory, along with recent advances in our internal chemistry program, I believe that Rodin has the potential to solidify a leadership role in the potential treatment of serious cognitive disorders.”
Mr. Rosenberg most recently served as co-founder, director and Chief Executive Officer at Teleos Therapeutics, a biotechnology company leveraging unique insights in zebrafish chemical biology and novel high throughput screening technologies to discover new treatments for central nervous system disorders. Mr. Rosenberg will retain this position until a successor is hired. He also co-founded and served on the Board of Directors of Clean Membranes, a materials company based on MIT technology, and since 2009 has advised or served in interim executive roles with numerous companies in the healthcare and biotechnology sectors, including leading the digital health strategy for Brightstar (acquired by SoftBank) and serving on the advisory board of Gecko Health Innovations (acquired by Teva Pharmaceuticals). From 2005 to 2009, he co-founded and served as CEO of Link Medicine Corporation, a company focused on developing novel disease-modifying neurodegenerative treatments. Link’s lead program was acquired by AstraZeneca. He also co-founded Faber Law Group, a boutique business law firm focused on the biotechnology sector. Previously, Mr. Rosenberg was a principal with Ovation Capital Partners, and worked in the corporate finance and venture capital groups at leading law firms in Boston, Seattle and New York. He also advised the production of A Late Quartet, a feature film starring Christopher Walken, Philip Seymour Hoffman and Catherine Keener, centered on a cellist in a world-class string quartet who is diagnosed with Parkinson’s disease. Mr. Rosenberg holds a BA from Whittier College and a JD from the University of Virginia School of Law.
About Rodin Therapeutics
Rodin Therapeutics is discovering and developing first in class therapeutics for cognitive disorders, applying unique insights into the role of epigenetics and best in class structural biology capabilities. Rodin closed a $12.9m Series A financing round in May 2014, and was co-founded in 2013 by Atlas Venture and Proteros Biostructures.
About Atlas Venture
Atlas Venture is a biotech-focused, early-stage venture capital firm that creates and invests in life sciences startup companies in the U.S. Atlas is based in Cambridge, Massachusetts. Since 1993, Atlas has invested in over 150 early stage life sciences companies. For more information, visit www.atlasventure-ls.com.
Director of Investor Relations and Marketing